Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Total Enrollment
91 participants
Study Classification
OBSERVATIONAL
Study Start Date
2025-11-01
Study Completion Date
2028-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Celiac disease (CD) is an autoimmune enteropathy triggered by the intake of gluten, characterized by a genetic predisposition. Although, CD is often associated with malabsorption symptoms, a growing number of affected subjects are overweight or frankly obese. One of the conditions that is most frequently detected in pauci/asymptomatic subjects is an increase in transaminases, which often regresses completely after the start of GFD.
More recently, a specific liver disorder has shown a certain relevance in adult patients suffering from CD, so much so that the European Society for the Study of Coeliac Disease (ESsCD) has cited it among the possible comorbidities which should be screened in CD subjects: Non-Alcoholic Fatty Liver Disease (NAFLD).
In adults, a non-random association between CD and NAFLD has been demonstrated, showing a CD prevalence rate of 2-14% among patients with NAFLD. Few studies have focused on this same aspect in pediatric age, reporting contrasting data.
Several factors have been advocated as putative responsible of association between CD and NAFLD: dietary imbalances, intestinal mucosa permeability impairment, alterations of the intestinal microbiota.
The objectives of this study are:
1. define, retrospectively, the prevalence of NAFLD in a pediatric population affected by CD and study its possible association with GFD.
2. define the possible role of the intestinal permeability alteration and/or the intestinal mucosa damage and/or the proinflammatory status in the development of NAFLD in children affected by CD.
More recently, a specific liver disorder has shown a certain relevance in adult patients suffering from CD, so much so that the European Society for the Study of Coeliac Disease (ESsCD) has cited it among the possible comorbidities which should be screened in CD subjects: Non-Alcoholic Fatty Liver Disease (NAFLD).
In adults, a non-random association between CD and NAFLD has been demonstrated, showing a CD prevalence rate of 2-14% among patients with NAFLD. Few studies have focused on this same aspect in pediatric age, reporting contrasting data.
Several factors have been advocated as putative responsible of association between CD and NAFLD: dietary imbalances, intestinal mucosa permeability impairment, alterations of the intestinal microbiota.
The objectives of this study are:
1. define, retrospectively, the prevalence of NAFLD in a pediatric population affected by CD and study its possible association with GFD.
2. define the possible role of the intestinal permeability alteration and/or the intestinal mucosa damage and/or the proinflammatory status in the development of NAFLD in children affected by CD.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Celiac Disease and Quality of Life in Children and Adolescents (CeliaQLife)
NCT06568263
Celiac Disease in Children
Nutritional Deficiency
Quality of Life
RECRUITING
Eating Behaviors in Children and Adolescents With/Without Celiac Disease
NCT07285512
Celiac Disease in Children
Eating Behaviors
NOT_YET_RECRUITING
Risk of Celiac Disease and Age at Gluten Introduction
NCT00639444
Celiac Disease
COMPLETED
NA
Intestinal Fatty Acid-binding Protein (I-FABP) Levels in Pediatric Celiac Patients
NCT03244254
Celiac Disease in Children
UNKNOWN
Characteristics of Anemia in Celiac Disease
NCT05172895
Celiac Disease
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background Celiac disease (CD), an autoimmune enteropathy triggered by the intake of gluten, is a widespread pathology, with a worldwide estimated prevalence of approximately 1%, characterized by both gastrointestinal and systemic symptoms, both in adults and children, which are usually resolved by eliminating gluten from the diet (Gluten-Free Diet, GFD). However, it still remains an under-diagnosed condition (to date the overall prevalence in Italy is 0.37% and in Sicily 0.35%).
Although, CD is often associated with malabsorption symptoms (steatorrhea, weight loss, nutritional deficits, etc.), a growing number of affected subjects are overweight or frankly obese. One of the conditions that is most frequently detected in pauci/asymptomatic subjects is an increase in transaminases, which often regresses completely after the start of GFD.
More recently, a specific liver disorder has shown a certain relevance in patients suffering from CD, so much so that the European Society for the Study of Coeliac Disease (ESsCD) has cited it among the possible comorbidities which should be screened in CD subjects: Non-Alcoholic Fatty Liver Disease (NAFLD). This condition affects approximately 34% of overweight or frankly obese children and is closely related, both in children and adults, to the traits of metabolic syndrome, so much so that today it is preferably referred to as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). In adults, a non-random association between CD and NAFLD has been demonstrated, showing a CD prevalence of 2-14% among patients with NAFLD. Few studies have focused on this same aspect in pediatric age, however reporting that the prevalence of CD among children with NAFLD could be comparable to the prevalence of CD in the general pediatric population. Nevertheless, a study conducted on 11488 children (0-19 years) affected by CD compared with 57029 healthy children supports the hypothesis of a close association between CD and NAFLD in childhood. Authors proved a 4.6 relative risk value of NAFLD in CD patients.
Several factors have been advocated as putative responsible for this association: 1) dietary imbalances due to the adoption of GFD, rich in fats and sugars and low in fiber; 2) alteration of intestinal permeability, with an increase in the translocation of bacterial substances from the gut, which, are transported directly to the liver, where they are able to generate inflammatory processes mediated by the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), activated by the Tool-like receptor 4 (TLR4)-Lipopolysaccharide (LPS)-LPS Binding Protein (LPB) complex, with production of proinflammatory cytokines \[Tumor Necrosis Factor (TNF)-α, Interleukine (IL)-1β, IL-6, IL-12, IL-18); 3) alterations of the intestinal microbiota.
Objectives
Primary objective: define, retrospectively, the prevalence of NAFLD in a pediatric population affected by CD and study its possible association with GFD:
Objective 1.1: identify the prevalence of NAFLD before the introduction of the GFD in an already diagnosed pediatric celiac; Objective 1.2: identify the prevalence of NAFLD after at least 12 months of GFD in an already diagnosed pediatric celiac; Objective 1.3: compare the prevalence of NAFLD before and after (at least 12 months) the introduction of the GFD in all pediatric celiac patients for whom both pre- and post-GFD data are available; Objective 1.4: establish a possible correlation between the presence/absence of NAFLD, both before and after the adoption of the GFD, and clinical, laboratory, immunological, genetic and histological parameters, in order to identify a subgroup of celiac children potentially predisposed to the NAFLD development; Objective 1.5: establish any changes in the clinical, laboratory, immunological, genetic and histological parameters of the population referred to in objective 1.3 and establish whether there is a correlation between these and the possible onset/regression of NAFLD.
Secondary objective: define the possible role of the intestinal permeability alteration and/or the intestinal mucosa damage and/or the proinflammatory status in the development of NAFLD in children affected by CD:
Objective 2.1: identify the possible presence of serological markers of altered intestinal permeability and/or intestinal mucosa damage in a population of celiac children prospectively enrolled at the Pediatric Clinic of the Children's Hospital "G. Di Cristina" before the start of the GFD (T0).
Objective 2.2: Identify the possible presence of blood markers of inflammation in the population referred to in point 2.1 at T0.
Objective 2.3: define the existence of an association between the markers of altered intestinal permeability and/or mucosal damage and/or inflammation and the presence of NAFLD in the population referred to in point 2.1 at T0.
Objective 2.4: evaluate any changes in serological markers of altered intestinal permeability and/or mucosal damage in the population referred to in point 2.1 after 6 months of strict adherence to the GFD (T1).
Objective 2.5: evaluate any changes in blood markers of inflammation in the population referred to in point 2.1 at T1.
Objective 2.6: define the existence of an association between the markers of altered intestinal permeability and/or mucosal damage and/or inflammation and the presence of NAFLD in the population referred to in point 2.1 at T1.
Materials and methods Primary objective To achieve the primary objective of the study, all the medical records of pediatric patients suffering from CD already diagnosed according to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria at the Pediatric Clinic of the Children's Hospital "G. Di Cristina" will be retrospectively analyzed.
Objectives 1.1, 1.2 and 1.3 To achieve objectives 1.1 and 1.2, the presence and degree of steatosis diagnosed by abdominal ultrasound will be assessed before the start of the GFD (objective 1.1) or after at least 12 months from the introduction of the GFD (objective 1.2).
To achieve objective 1.3, a sub-analysis of the presence and degree of steatosis will be performed in all those patients who have undergone an abdominal ultrasound both before and after the introduction of GFD.
Objectives 1.4 and 1.5 To achieve objective 1.4, clinical (sex, ethnicity, age at diagnosis, BMI, symptoms, duration of GFD), laboratory (transaminasemia, albuminemia, total cholesterolemia and subclasses, triglyceridemia, fasting glycemia, insulinemia, Homeostasis Model Assessment-Insulin Resistance HOMA-IR Index), immunological \[anti-gliadin antibodies (AGA), anti-tissue transglutaminase antibodies (tTG), anti-endomysial antibodies (EMA)\], genetic (HLA structure) and histological (Marsh duodenal histological classification, presence of eosinophilic infiltration, etc.) data of all included patients will be collect, both before (target population 1.1) and after (target population 1.2) the introduction of the GFD.
To achieve objective 1.5, the same clinical, laboratory, immunological, genetic and histological parameters analyzed for objective 1.4 will be analyzed, if available both before and after the introduction of the GFD, in order to establish whether there is a correlation between these and the possible onset/regression of NAFLD in the population referred to in objective 1.3.
Secondary objective To achieve the secondary objective of the study, pediatric patients affected by newly diagnosed CD according to the ESPGHAN criteria will be prospectively enrolled at the at the Pediatric Clinic of the Children's Hospital "G. Di Cristina". The number of subjects to be enrolled will be equal to 91, considering, in the Province of Palermo, Sicily, Italy, a pediatric population (between 0 and 14 years) of 170,468 subjects, a prevalence of CD equal to 1%, a confidence level of 95% and a confidence interval of 10%. Furthermore, as the exact prevalence of NAFLD in children with CD it's not clearly defined, results derived from the retrospective part of this study (objective 1.1) will be used to maintain a proportion between subjects enrolled without and with pre-GFD NAFLD ("competitive enrollment").
Objectives 2.1, 2.2, 2.3 To achieve objective 2.1, all enrolled subjects, for whom the same clinical, laboratory, immunological, genetic and histological parameters analyzed for objective 1.4 must be available (the latter only if necessary for diagnosis), in order to make a comparison possible, will be subjected to blood sampling for the identification of serological markers of altered intestinal permeability \[zonulin (Zo), occludin (OCLN), anti-OCLN antibodies, claudin 1 (CLDN1) and anti-CLDN1 antibodies\] and mucosal damage \[Intestinal Fatty Acid Binding Protein 2 (iFABP2)\], lipopolysaccharide (LPS), lipopolysaccharide binding protein (LPB)\] before starting the GFD (T0). The blood sampling will coincide with the one necessary for the diagnostic definition of the patient's clinical picture.
To achieve objective 2.2, all enrolled subjects will undergo a blood sample before starting the GFD (T0), for the identification of the following inflammatory markers: TNF-α, IL-1β, IL-6, IL-12, IL-18. The blood sampling will coincide with the one necessary for the diagnostic definition of the patient's clinical picture.
To achieve objective 2.3, all enrolled subjects, before starting the GFD (T0), will undergo an abdominal ultrasound to study hepatic steatosis according to the methods previously described and a statistical correlation analysis will be carried out between the presence/absence of NAFLD and the markers assayed for objective 2.1 and 2.2.
The assay of intestinal permeability and mucosal damage markers will be carried out using the ELISA method, with commercially available kits, following the manufacturers' instructions.
The measurement of inflammation markers will be performed by intracellular staining with flow cytometric method on peripheral blood mononuclear cells (PBMC) extracted from patients' blood samples.
Objectives 2.4, 2.5, 2.6 To achieve objective 2.4, all enrolled subjects, for whom the same clinical, laboratory and immunological parameters analyzed at T0 must be available, in order to make a comparison possible, will be subjected to a blood sample for the identification of serological markers of altered intestinal permeability and mucosal damage already measured at T0 (see objective 2.1), after 6 months of strict adherence to the GFD (T1). The blood sampling will coincide with the one necessary to re-evaluate the patient's clinical picture after 6 months of adherence to the GFD.
To achieve objective 2.5, all enrolled subjects will undergo a blood sample to identify the inflammation markers already dosed at T0 (see objective 2.2), after 6 months of strict adherence to the GFD (T1). The blood sampling will coincide with the one necessary to re-evaluate the patient's clinical picture after 6 months of adherence to the GFD.
To achieve objective 2.6, all enrolled subjects, after 6 months of strict adherence to the GFD (T1), will undergo abdominal ultrasound to study hepatic steatosis according to the methods previously described and a statistical correlation analysis will be carried out between the presence/absence of NAFLD and the markers assayed for objective 2.4 and 2.5.
The assessment of adherence to the GFD will be carried out through the monthly compilation, by the children and/or their parents, of a specifically created and validated questionnaire.
Although, CD is often associated with malabsorption symptoms (steatorrhea, weight loss, nutritional deficits, etc.), a growing number of affected subjects are overweight or frankly obese. One of the conditions that is most frequently detected in pauci/asymptomatic subjects is an increase in transaminases, which often regresses completely after the start of GFD.
More recently, a specific liver disorder has shown a certain relevance in patients suffering from CD, so much so that the European Society for the Study of Coeliac Disease (ESsCD) has cited it among the possible comorbidities which should be screened in CD subjects: Non-Alcoholic Fatty Liver Disease (NAFLD). This condition affects approximately 34% of overweight or frankly obese children and is closely related, both in children and adults, to the traits of metabolic syndrome, so much so that today it is preferably referred to as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). In adults, a non-random association between CD and NAFLD has been demonstrated, showing a CD prevalence of 2-14% among patients with NAFLD. Few studies have focused on this same aspect in pediatric age, however reporting that the prevalence of CD among children with NAFLD could be comparable to the prevalence of CD in the general pediatric population. Nevertheless, a study conducted on 11488 children (0-19 years) affected by CD compared with 57029 healthy children supports the hypothesis of a close association between CD and NAFLD in childhood. Authors proved a 4.6 relative risk value of NAFLD in CD patients.
Several factors have been advocated as putative responsible for this association: 1) dietary imbalances due to the adoption of GFD, rich in fats and sugars and low in fiber; 2) alteration of intestinal permeability, with an increase in the translocation of bacterial substances from the gut, which, are transported directly to the liver, where they are able to generate inflammatory processes mediated by the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB), activated by the Tool-like receptor 4 (TLR4)-Lipopolysaccharide (LPS)-LPS Binding Protein (LPB) complex, with production of proinflammatory cytokines \[Tumor Necrosis Factor (TNF)-α, Interleukine (IL)-1β, IL-6, IL-12, IL-18); 3) alterations of the intestinal microbiota.
Objectives
Primary objective: define, retrospectively, the prevalence of NAFLD in a pediatric population affected by CD and study its possible association with GFD:
Objective 1.1: identify the prevalence of NAFLD before the introduction of the GFD in an already diagnosed pediatric celiac; Objective 1.2: identify the prevalence of NAFLD after at least 12 months of GFD in an already diagnosed pediatric celiac; Objective 1.3: compare the prevalence of NAFLD before and after (at least 12 months) the introduction of the GFD in all pediatric celiac patients for whom both pre- and post-GFD data are available; Objective 1.4: establish a possible correlation between the presence/absence of NAFLD, both before and after the adoption of the GFD, and clinical, laboratory, immunological, genetic and histological parameters, in order to identify a subgroup of celiac children potentially predisposed to the NAFLD development; Objective 1.5: establish any changes in the clinical, laboratory, immunological, genetic and histological parameters of the population referred to in objective 1.3 and establish whether there is a correlation between these and the possible onset/regression of NAFLD.
Secondary objective: define the possible role of the intestinal permeability alteration and/or the intestinal mucosa damage and/or the proinflammatory status in the development of NAFLD in children affected by CD:
Objective 2.1: identify the possible presence of serological markers of altered intestinal permeability and/or intestinal mucosa damage in a population of celiac children prospectively enrolled at the Pediatric Clinic of the Children's Hospital "G. Di Cristina" before the start of the GFD (T0).
Objective 2.2: Identify the possible presence of blood markers of inflammation in the population referred to in point 2.1 at T0.
Objective 2.3: define the existence of an association between the markers of altered intestinal permeability and/or mucosal damage and/or inflammation and the presence of NAFLD in the population referred to in point 2.1 at T0.
Objective 2.4: evaluate any changes in serological markers of altered intestinal permeability and/or mucosal damage in the population referred to in point 2.1 after 6 months of strict adherence to the GFD (T1).
Objective 2.5: evaluate any changes in blood markers of inflammation in the population referred to in point 2.1 at T1.
Objective 2.6: define the existence of an association between the markers of altered intestinal permeability and/or mucosal damage and/or inflammation and the presence of NAFLD in the population referred to in point 2.1 at T1.
Materials and methods Primary objective To achieve the primary objective of the study, all the medical records of pediatric patients suffering from CD already diagnosed according to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria at the Pediatric Clinic of the Children's Hospital "G. Di Cristina" will be retrospectively analyzed.
Objectives 1.1, 1.2 and 1.3 To achieve objectives 1.1 and 1.2, the presence and degree of steatosis diagnosed by abdominal ultrasound will be assessed before the start of the GFD (objective 1.1) or after at least 12 months from the introduction of the GFD (objective 1.2).
To achieve objective 1.3, a sub-analysis of the presence and degree of steatosis will be performed in all those patients who have undergone an abdominal ultrasound both before and after the introduction of GFD.
Objectives 1.4 and 1.5 To achieve objective 1.4, clinical (sex, ethnicity, age at diagnosis, BMI, symptoms, duration of GFD), laboratory (transaminasemia, albuminemia, total cholesterolemia and subclasses, triglyceridemia, fasting glycemia, insulinemia, Homeostasis Model Assessment-Insulin Resistance HOMA-IR Index), immunological \[anti-gliadin antibodies (AGA), anti-tissue transglutaminase antibodies (tTG), anti-endomysial antibodies (EMA)\], genetic (HLA structure) and histological (Marsh duodenal histological classification, presence of eosinophilic infiltration, etc.) data of all included patients will be collect, both before (target population 1.1) and after (target population 1.2) the introduction of the GFD.
To achieve objective 1.5, the same clinical, laboratory, immunological, genetic and histological parameters analyzed for objective 1.4 will be analyzed, if available both before and after the introduction of the GFD, in order to establish whether there is a correlation between these and the possible onset/regression of NAFLD in the population referred to in objective 1.3.
Secondary objective To achieve the secondary objective of the study, pediatric patients affected by newly diagnosed CD according to the ESPGHAN criteria will be prospectively enrolled at the at the Pediatric Clinic of the Children's Hospital "G. Di Cristina". The number of subjects to be enrolled will be equal to 91, considering, in the Province of Palermo, Sicily, Italy, a pediatric population (between 0 and 14 years) of 170,468 subjects, a prevalence of CD equal to 1%, a confidence level of 95% and a confidence interval of 10%. Furthermore, as the exact prevalence of NAFLD in children with CD it's not clearly defined, results derived from the retrospective part of this study (objective 1.1) will be used to maintain a proportion between subjects enrolled without and with pre-GFD NAFLD ("competitive enrollment").
Objectives 2.1, 2.2, 2.3 To achieve objective 2.1, all enrolled subjects, for whom the same clinical, laboratory, immunological, genetic and histological parameters analyzed for objective 1.4 must be available (the latter only if necessary for diagnosis), in order to make a comparison possible, will be subjected to blood sampling for the identification of serological markers of altered intestinal permeability \[zonulin (Zo), occludin (OCLN), anti-OCLN antibodies, claudin 1 (CLDN1) and anti-CLDN1 antibodies\] and mucosal damage \[Intestinal Fatty Acid Binding Protein 2 (iFABP2)\], lipopolysaccharide (LPS), lipopolysaccharide binding protein (LPB)\] before starting the GFD (T0). The blood sampling will coincide with the one necessary for the diagnostic definition of the patient's clinical picture.
To achieve objective 2.2, all enrolled subjects will undergo a blood sample before starting the GFD (T0), for the identification of the following inflammatory markers: TNF-α, IL-1β, IL-6, IL-12, IL-18. The blood sampling will coincide with the one necessary for the diagnostic definition of the patient's clinical picture.
To achieve objective 2.3, all enrolled subjects, before starting the GFD (T0), will undergo an abdominal ultrasound to study hepatic steatosis according to the methods previously described and a statistical correlation analysis will be carried out between the presence/absence of NAFLD and the markers assayed for objective 2.1 and 2.2.
The assay of intestinal permeability and mucosal damage markers will be carried out using the ELISA method, with commercially available kits, following the manufacturers' instructions.
The measurement of inflammation markers will be performed by intracellular staining with flow cytometric method on peripheral blood mononuclear cells (PBMC) extracted from patients' blood samples.
Objectives 2.4, 2.5, 2.6 To achieve objective 2.4, all enrolled subjects, for whom the same clinical, laboratory and immunological parameters analyzed at T0 must be available, in order to make a comparison possible, will be subjected to a blood sample for the identification of serological markers of altered intestinal permeability and mucosal damage already measured at T0 (see objective 2.1), after 6 months of strict adherence to the GFD (T1). The blood sampling will coincide with the one necessary to re-evaluate the patient's clinical picture after 6 months of adherence to the GFD.
To achieve objective 2.5, all enrolled subjects will undergo a blood sample to identify the inflammation markers already dosed at T0 (see objective 2.2), after 6 months of strict adherence to the GFD (T1). The blood sampling will coincide with the one necessary to re-evaluate the patient's clinical picture after 6 months of adherence to the GFD.
To achieve objective 2.6, all enrolled subjects, after 6 months of strict adherence to the GFD (T1), will undergo abdominal ultrasound to study hepatic steatosis according to the methods previously described and a statistical correlation analysis will be carried out between the presence/absence of NAFLD and the markers assayed for objective 2.4 and 2.5.
The assessment of adherence to the GFD will be carried out through the monthly compilation, by the children and/or their parents, of a specifically created and validated questionnaire.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Celiac Disease in Children
Non-Alcoholic Fatty Liver Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Celiac Disease Children
Pediatric patients affected by newly diagnosed CD according to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria will be evaluated before the start of gluten-free diet and after 6 months of gluten-free diet.
Gluten-free diet
Intervention Type
BEHAVIORAL
Pediatric patients affected by newly diagnosed Celiac Disease (CD) according to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria will start a gluten-free diet (GFD), as normally expected for all CD patients. The assessment of adherence to the GFD will be carried out through the monthly compilation, by the children and/or their parents, of a specifically created and validated questionnaire.
Before and after the start of GFD enrolled patients will undergo an abdominal ultrasound to establish the presence and degree of hepatic steatosis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gluten-free diet
Pediatric patients affected by newly diagnosed Celiac Disease (CD) according to the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria will start a gluten-free diet (GFD), as normally expected for all CD patients. The assessment of adherence to the GFD will be carried out through the monthly compilation, by the children and/or their parents, of a specifically created and validated questionnaire.
Before and after the start of GFD enrolled patients will undergo an abdominal ultrasound to establish the presence and degree of hepatic steatosis.
Intervention Type
BEHAVIORAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>1 and \<14 years
* Celiac Disease diagnosis according European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria
* Celiac Disease diagnosis according European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) criteria
Exclusion Criteria
* age \<1 and \>14 years;
* self-exclusion of gluten/wheat from the diet and refusal to reintroduce it, for diagnostic purposes, before entering the study;
* bacterial and/or parasitic infections;
* diagnosis of chronic inflammatory intestinal diseases and other organic pathologies affecting the digestive system (for example, serious liver diseases), nervous system diseases, immunological deficits and impairments that limit physical activity;
* diagnosis of cancer
* patients undergoing chemotherapy and/or radiotherapy.
* self-exclusion of gluten/wheat from the diet and refusal to reintroduce it, for diagnostic purposes, before entering the study;
* bacterial and/or parasitic infections;
* diagnosis of chronic inflammatory intestinal diseases and other organic pathologies affecting the digestive system (for example, serious liver diseases), nervous system diseases, immunological deficits and impairments that limit physical activity;
* diagnosis of cancer
* patients undergoing chemotherapy and/or radiotherapy.
Minimum Eligible Age
1 Year
Maximum Eligible Age
14 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ARNAS Civico Di Cristina Benfratelli Hospital
OTHER
Sponsor Role
collaborator
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
OTHER
Sponsor Role
collaborator
University of Palermo
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aurelio Seidita
Assistant Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gastroenterological Paediatrics, Children's Hospital "G. Di Cristina"
Palermo, Palermo, Italy
Site Status
General Pediatrics Unit, Children's Hospital "G. Di Cristina"
Palermo, Palermo, Italy
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
00390916666245
References
Explore related publications, articles, or registry entries linked to this study.
Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D, Catassi C, Lelgeman M, Maki M, Ribes-Koninckx C, Ventura A, Zimmer KP; ESPGHAN Working Group on Coeliac Disease Diagnosis; ESPGHAN Gastroenterology Committee; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):136-60. doi: 10.1097/MPG.0b013e31821a23d0.
Reference Type
BACKGROUND
Mansueto P, Spagnuolo G, Calderone S, D'Agate CC, Cosenza S, Leonardi G, Camilleri S, Pistone M, Seminara G, Alaimo C, Soresi M, Carroccio A, Garufi S. Improving the diagnostic approach to celiac disease: Experience from a regional network. Dig Liver Dis. 2022 Jun;54(6):771-775. doi: 10.1016/j.dld.2021.11.016. Epub 2021 Dec 21.
Reference Type
BACKGROUND
Al-Toma A, Volta U, Auricchio R, Castillejo G, Sanders DS, Cellier C, Mulder CJ, Lundin KEA. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterol J. 2019 Jun;7(5):583-613. doi: 10.1177/2050640619844125. Epub 2019 Apr 13.
Reference Type
BACKGROUND
Yoosuf S, Singh P, Khaitan A, Strand TA, Ahuja V, Makharia GK. Prevalence of Celiac Disease in Patients With Liver Diseases: A Systematic Review and Meta-Analyses. Am J Gastroenterol. 2023 May 1;118(5):820-832. doi: 10.14309/ajg.0000000000002123. Epub 2022 Dec 23.
Reference Type
BACKGROUND
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gomez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
Reference Type
BACKGROUND
Yodoshi T, Orkin S, Arce-Clachar AC, Bramlage K, Xanthakos SA, Valentino PL, Mouzaki M. Alternative Etiologies of Liver Disease in Children With Suspected NAFLD. Pediatrics. 2021 Apr;147(4):e2020009829. doi: 10.1542/peds.2020-009829.
Reference Type
BACKGROUND
Reilly NR, Lebwohl B, Hultcrantz R, Green PH, Ludvigsson JF. Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease. J Hepatol. 2015 Jun;62(6):1405-11. doi: 10.1016/j.jhep.2015.01.013. Epub 2015 Jan 21.
Reference Type
BACKGROUND
Spadoni I, Zagato E, Bertocchi A, Paolinelli R, Hot E, Di Sabatino A, Caprioli F, Bottiglieri L, Oldani A, Viale G, Penna G, Dejana E, Rescigno M. A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015 Nov 13;350(6262):830-4. doi: 10.1126/science.aad0135.
Reference Type
BACKGROUND
Wang HH, Lee DK, Liu M, Portincasa P, Wang DQ. Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome. Pediatr Gastroenterol Hepatol Nutr. 2020 May;23(3):189-230. doi: 10.5223/pghn.2020.23.3.189. Epub 2020 May 8.
Reference Type
BACKGROUND
Hrncir T, Hrncirova L, Kverka M, Hromadka R, Machova V, Trckova E, Kostovcikova K, Kralickova P, Krejsek J, Tlaskalova-Hogenova H. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. Microorganisms. 2021 Apr 29;9(5):957. doi: 10.3390/microorganisms9050957.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ASAC01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Dietary Assessment and Mycotoxin Exposure in Celiac Disease
NCT01975155
UNKNOWN
Infant Nutrition and Risk of Celiac Disease
NCT00819819
TERMINATED
NA
Multicenter Study on the Toxicity of Gluten Traces in the Treatment of Celiac Disease
NCT00250146
TERMINATED
NA
Validation of a New Innovative Method for Specific Marker Detection in Celiac Disease
NCT06324539
RECRUITING
Mental Perfomance in Patients With Coeliac Disease
NCT06519916
COMPLETED
SCREENING OF CELIAC DISEASE IN SCHOLAR CHILDREN IN ITALY
NCT04867863
COMPLETED
Randomized Clincal Trial on the Effect of a Restricted Gluten Contamination Elimination Diet Among Celiacs [GluCED]
NCT02711696
COMPLETED
NA
Development of CELIAC-Q KIDS: A Patient-Reported Outcome Measure for Pediatric Celiac Disease
NCT05548166
ACTIVE_NOT_RECRUITING
Supporting Children and Young People to Live Well with Coeliac Disease
NCT06007898
COMPLETED
NA
Host-Diet-Gut Interaction Post Vegan Diet in Pediatric Autoimmune Hepatitis.
NCT07118657
NOT_YET_RECRUITING
NA
Detection of Immunotoxic Gluten Peptides in Feces
NCT01478867
COMPLETED
Preservation of Residual Beta Cell Mass and Prevention of Celiac Disease in Children With Recent Onset Type 1 Diabetes
NCT03037190
UNKNOWN
NA
Saliva Composition and Oral Hygiene in Children With Celiac Disease Before and After the Change in Diet
NCT01129908
COMPLETED
Support for Adolescents With Celiac Disease
NCT04533776
COMPLETED
NA
Gluten-related Disorders in Familial Mediterranean Fever Patients
NCT03563300
COMPLETED
NA
Assessment of the Effect of Gluten Free Toothpaste on the Ulcerative Events in Children With Celiac Disease
NCT03771443
COMPLETED
PHASE3
Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women
NCT05052164
COMPLETED
NA
Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo
NCT02472704
COMPLETED
NA
Cardiovascular Risk Factors in Coeliac Disease: a Series of Studies
NCT05530070
RECRUITING
NA
TCRγδ+ Cells After Gluten-free Diet: A Biomarker for Coeliac Disease?
NCT05733663
COMPLETED
Quantification of Gluten Peptides in Feces
NCT02711397
COMPLETED
Celiac Disease Prevention
NCT00617838
UNKNOWN
NA
Serological Identification of Celiac Disease in Kids
NCT03966625
COMPLETED
Celiac Disease in Children
NCT06783673
COMPLETED